Novartis is suing HRSA to impose a controversial 340B rebate model that the agency has not authorized.

Novartis is Fifth Drugmaker to Sue HRSA to Implement Controversial 340B Rebate Model

January 17, 2025 William Newton, Associate Editor/Senior Writer 340B Report Views

Novartis this week became the fifth manufacturer to sue the Health Resources and Services Administration (HRSA) to implement a 340B [...]

Please Login or Become a Paid Subscriber to View this Content

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!